Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1983 2
1985 1
1986 1
1987 1
1988 1
1989 2
1990 1
1991 2
1992 1
1993 2
1994 1
1995 4
1996 1
1997 4
1998 8
1999 8
2000 9
2001 15
2002 12
2003 19
2004 10
2005 19
2006 19
2007 22
2008 29
2009 30
2010 23
2011 22
2012 49
2013 50
2014 58
2015 84
2016 93
2017 106
2018 87
2019 60
2020 61
2021 57
2022 61
2023 46
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

931 results

Results by year

Filters applied: . Clear all
Page 1
Acute kidney injury in neurocritical care.
Husain-Syed F, Takeuchi T, Neyra JA, Ramírez-Guerrero G, Rosner MH, Ronco C, Tolwani AJ. Husain-Syed F, et al. Crit Care. 2023 Sep 3;27(1):341. doi: 10.1186/s13054-023-04632-1. Crit Care. 2023. PMID: 37661277 Free PMC article. Review.
Approximately 20% of patients with acute brain injury (ABI) also experience acute kidney injury (AKI), which worsens their outcomes. ...As a result, recognizing its presence is important for effectively managing ABI and its sequelae. This review discusses the occurr …
Approximately 20% of patients with acute brain injury (ABI) also experience acute kidney injury (AKI), which worsens their outcomes. …
ABI-auditory brainstem implant.
Dhanasingh A, Hochmair I. Dhanasingh A, et al. Acta Otolaryngol. 2021 Mar;141(sup1):63-81. doi: 10.1080/00016489.2021.1888486. Acta Otolaryngol. 2021. PMID: 33818262
At MED-EL, the early development activities on ABI started in the year 1994, with the suggestion coming from J. ...Key translational research activities at MED-EL in collaboration with numerous clinics investigating the factors that affect the hearing performance amongst …
At MED-EL, the early development activities on ABI started in the year 1994, with the suggestion coming from J. ...Key translational …
Abi Family Protein, DidK, Is Involved in the Maturation of Anticancer Depsipeptide, Didemnin B.
Jia K, Wang J, Zhai R, Du Y, Kira J, Wu C, Qian PY, Zhang W. Jia K, et al. ACS Chem Biol. 2023 Oct 20;18(10):2300-2308. doi: 10.1021/acschembio.3c00393. Epub 2023 Sep 29. ACS Chem Biol. 2023. PMID: 37773034
We further identified an Abi family transmembrane protease, DidK, that functioned as an esterase in the maturation step of didemnin B by in vivo gene knockout and heterologous expression. ...These results not only clarify the priming and maturation steps of didemnin …
We further identified an Abi family transmembrane protease, DidK, that functioned as an esterase in the maturation step of didemnin …
Advances in hepatitis B therapeutics.
Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Soriano V, et al. Ther Adv Infect Dis. 2020 Oct 15;7:2049936120965027. doi: 10.1177/2049936120965027. eCollection 2020 Jan-Dec. Ther Adv Infect Dis. 2020. PMID: 33117536 Free PMC article. Review.
Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of hepatocellular carcinoma, which represents th …
Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with th …
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
Agarwal K, Xu J, Gane EJ, Nguyen TT, Ding Y, Knox SJ, Alves K, Evanchik M, Zomorodi K, Ma J, Yan R, Huang Q, Colonno R, Stamm LM, Hassanein TI, Kim DJ, Lim YS, Yuen MF. Agarwal K, et al. J Viral Hepat. 2023 Mar;30(3):209-222. doi: 10.1111/jvh.13764. Epub 2023 Jan 12. J Viral Hepat. 2023. PMID: 36302125 Clinical Trial.
We report safety, pharmacokinetics and antiviral activity of the investigational HBV core inhibitor ABI-H2158. This Phase 1a/b study (NCT03714152) had three parts: Part A, participants received a single ascending oral dose of ABI-H2158 (5-500 mg) or placebo; …
We report safety, pharmacokinetics and antiviral activity of the investigational HBV core inhibitor ABI-H2158. This Phase 1a/b …
An Alternate Explanation.
Alsaigh T, Dhaliwal G, Fukaya E, Leeper NJ, Sayed N. Alsaigh T, et al. N Engl J Med. 2023 Apr 6;388(14):1318-1324. doi: 10.1056/NEJMcps2210419. N Engl J Med. 2023. PMID: 37018496 Free PMC article.
His physical examination showed reduced light-touch sensation in a glove-and-stocking distribution; the radial and pedal pulses were palpable. The vitamin B(12) level was 260 pg per milliliter (192 pmol per liter; normal range, 190 to 950 pg per milliliter [140 to 701 pmol …
His physical examination showed reduced light-touch sensation in a glove-and-stocking distribution; the radial and pedal pulses were palpabl …
Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731.
Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Huang Q, et al. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20. doi: 10.1128/AAC.01463-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32868329 Free PMC article.
ABI-H0731, a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity in chronic hepatitis B (CHB) patients in a phase 1b clinical trial and is currently being further evaluated in phase 2 clinical trials. …
ABI-H0731, a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity in …
Validation of Acoustic Breathiness Index (ABI) in the South Indian Population.
Jayakumar T, Benoy JJ. Jayakumar T, et al. J Voice. 2022 Jun 8:S0892-1997(22)00139-4. doi: 10.1016/j.jvoice.2022.05.006. Online ahead of print. J Voice. 2022. PMID: 35690529
The authors observed neither language nor gender differences in ABI. The concurrent validity of ABI was strong (r = 0.761) when correlated against "B". ...ABI correlates better with "B" than "G" on the GRBAS scale. ABI is independent of l …
The authors observed neither language nor gender differences in ABI. The concurrent validity of ABI was strong (r = 0.761) whe …
Developing Social-ABI-lity: An Online Course to Support Safe Use of Social Media for Connection After Acquired Brain Injury.
Brunner M, Rietdijk R, Avramovic P, Power E, Miao M, Rushworth N, MacLean L, Brookes AM, Togher L. Brunner M, et al. Am J Speech Lang Pathol. 2023 Mar 23;32(2S):924-940. doi: 10.1044/2022_AJSLP-22-00099. Epub 2022 Dec 9. Am J Speech Lang Pathol. 2023. PMID: 36492293 Review.
We aimed to develop a collaboratively designed, evidence-based online training resource to support people with an ABI to learn about using social media. Key recommendations for course design have previously been identified through a mixed methods approach, including (a) qu …
We aimed to develop a collaboratively designed, evidence-based online training resource to support people with an ABI to learn about …
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, Lim YS, Cheng W, Sievert W, Visvanathan K, Ruby E, Liaw S, Yan R, Huang Q, Colonno R, Lopatin U. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166. doi: 10.1016/S2468-1253(19)30346-2. Epub 2019 Nov 9. Lancet Gastroenterol Hepatol. 2020. PMID: 31711752 Clinical Trial.
METHODS: This phase 1, randomised, placebo-controlled study was done in two parts. In part 1, healthy adults without hepatitis B aged 18-65 years at one clinical research centre in New Zealand (eight participants per dose cohort) were randomly assigned (3:1) to receive sin …
METHODS: This phase 1, randomised, placebo-controlled study was done in two parts. In part 1, healthy adults without hepatitis B aged …
931 results